Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8541954 | 1.00 | MEN1 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL3717223 | 0.98 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL7992297 | 0.92 | MKNK1 (0.55) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL6179719 | 0.92 | MKNK1 (0.55) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL165154 | 0.92 | MKNK1 (0.55) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL11510901 | 0.82 | MKNK1 (0.48) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL25625502 | 0.81 | MAPT (0.48) | MEN1CYP2D6KMT2ACHRNB2CHRNA4 | |
| SCHEMBL24313467 | 0.81 | MEN1 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL10475820 | 0.81 | MEN1 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL8153240 | 0.81 | MEN1 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169156-A1 | Azacyclooctane and heptane derivatives, their preparation and use in therapy | NEUROSEARCH A/S | 2002-11-14 | — | — | US | claimed |
| EP-1150963-A1 | SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046214-A1 | SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-08-10 | — | — | WO | disclosed |
| EP-0705259-B1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-02-25 | — | — | EP | disclosed |
| EP-0705259-A1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000508-A1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169156-A1 | Azacyclooctane and heptane derivatives, their preparation and use in therapy | CHRNA1, CHRNB1, CHRNA3 | MEN1 3141/4885CYP2D6 1142/4885CYP2C19 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.